Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
- Resource Type
- Article
- Source
- Breast Care; 2024, Vol. 19 Issue 1, p1-9, 8p
- Subject
THERAPEUTIC use of antineoplastic agents ADJUVANT chemotherapy DRUG efficacy RESEARCH CLINICAL trials EPIDERMAL growth factor receptors ANTINEOPLASTIC agents PROTEIN-tyrosine kinase inhibitors DRUGS DESCRIPTIVE statistics RESEARCH funding PATIENT compliance HORMONE receptor positive breast cancer BREAST tumors LONGITUDINAL method EVALUATION - Language
- ISSN
- 16613791